Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Herantis Pharma secures important financing to support development efforts. The specific funding amount and lead investors were not disclosed in the recent report.
PRIVATEAug 20, 2026•about 7 hours ago
Round Type
Venture - Series Unknown
EspooBiotechnologyHealth CareTherapeutics
Description
Herantis Pharma Plc has announced a productive first half of 2026, highlighted by secured important financing for its ongoing projects. This funding will support the development of disease-modifying therapies for Parkinson’s disease. Although specific details on the funding amount and investors were not disclosed, the company reaffirms its commitment to advancing its therapeutic programs. The CEO noted these achievements enhance the company's readiness for the next stage of development.
Company Information
Company
Herantis Pharma
Location
Espoo, Uusimaa, Finland
About
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2027 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.
Don't miss Herantis Pharma's next move
Get an email the moment Herantis Pharma raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Herantis Pharma's next move
EspooBiotechnologyHealth CareTherapeutics